Forty Seven, a GV-backed immuno-oncology spinout from Stanford University, has filed for a $115m initial public offering on Nasdaq just eight months after closing a $75m series B.

UCL spinout Autolus has filed for an initial public offering on Nasdaq and plans on using the proceeds to further develop its range of cancer treatments.

The cancer immunotherapy developer, backed by Stanford University, has closed the offering after the underwriters bought another $18m of shares.

Cancer immunotherapy developer Arcus Biosciences will float at the top of its range, scoring an exit for Stanford University.

ETH Zurich spinout Sensirion hopes to capture $58m by going public later this month in an offering that will position co-founders Felix Mayer and Moritz Lechner as anchor shareholders.

Stanford University is set to exit the cancer immunotherapy developer, which has filed for a $100m initial public offering.

University of Minnesota spinout Calyxt has entered the public markets in a flotation that resulted in the share price climbing from $8 to $11.25 on the first day of trading.

University of Surrey in-video advertising spinout Mirriad is set to raise $35m in an initial public offering at a market cap of $84.4m.

Quanterix, a digital immunoassay developer spun out of Tufts University, has raised $64.1m in its initial public offering.

Queen's University spinout Fusion Antibodies is targeting $7.4m in proceeds in an IPO that will provide an exit to Qubis and Invest NI.